Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects-Reference-Cited by-同舟云学术

Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects

Published:2015-05-22 Issue:6 Volume:79 Page:907-917
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Moore Kenneth Todd¹,Byra William²,Vaidyanathan Seema³,Natarajan Jaya²,Ariyawansa Jay²,Salih Hiba⁴,Turner Kenneth C.¹

Affiliation:

1. Janssen Research & Development, LLC Titusville NJ

2. Janssen Research & Development, LLC Raritan NJ

3. Janssen Research & Development, LLC Springhouse PA USA

4. Clinical Pharmacology Unit Janssen Pharmaceutica NV Antwerp Belgium

Funder

Janssen Research & Development, LLC

Bayer HealthCare Pharmaceuticals

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.12559

Reference15 articles.

1. Bayer Pharma AG.Xarelto® (rivaroxaban) Summary of Product Characteristics.2014. Available athttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000944/WC500057108.pdf(last accessed 23 December 2014).

2. Janssen Pharmaceuticals Inc.Xarelto® (rivaroxaban) Prescribing Information.2014. Available athttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202439s008lbl.pdf(last accessed 7 January 2015).

3. Bristol‐Myers Squibb.Coumadin (warfarin sodium) Prescribing Information.2011. Available athttp://packageinserts.bms.com/pi/pi_coumadin.pdf(last accessed 6 August 2014).

4. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects

5. Determination of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – in human plasma by high-performance liquid chromatography–tandem mass spectrometry

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants;Frontiers in Pharmacology;2023-05-19

2. References;Genesis, Pathophysiology and Management of Venous and Lymphatic Disorders;2022

3. Recurrent Thrombi in an Obese Patient With History of Bariatric Surgery Despite Anti-Xa Therapy;Journal of Pharmacy Practice;2021-04-08

4. Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase;Journal of Personalized Medicine;2021-03-30

5. Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients;Blood Advances;2018-05-14